Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

328
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
328
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

287
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
287
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

302
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
302
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

765
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
765
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

291
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
291
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

273
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
273

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalent versus incident progressive supranuclear palsy: An analysis of the frequencies of neuropathological and clinical features at U.S. Alzheimer's Disease Research Centers indicate a relatively common tauopathy of aging.

Research square·2026
Same author

Relationships between longitudinal retinal amyloid imaging and amyloid PET in the A4 Trial.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Provider and patient perspectives on the diagnosis and treatment of Alzheimer's disease: A global perspective from the Global Alzheimer's Leadership Series (GoALS).

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Frontal Release Signs and Future Decline in Research Participants With Intact Cognition.

JAMA network open·2026
Same author

GRN rs5848 variant associates with TDP-43 pathology and cancer in opposite directions.

Journal of neuropathology and experimental neurology·2026

Related Experiment Video

Updated: Mar 2, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K

Optimizing medication appropriateness in older adults: a randomized clinical interventional trial to decrease

Daniela C Moga1,2,3, Erin L Abner4,5, Dorinda N Rigsby6

  • 1Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, 789 S Limestone Street, Room 241, Lexington, KY, 40536, USA. daniela.moga@uky.edu.

Alzheimer'S Research & Therapy
|May 25, 2017
PubMed
Summary
This summary is machine-generated.

A targeted medication therapy management intervention improved the appropriateness of anticholinergic medication use in older adults. This pharmacist-physician team approach reduced health risks associated with these medications.

Keywords:
Alzheimer’s Disease CenterAnticholinergic medicationMedication therapy management interventionOlder adults

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Related Experiment Videos

Last Updated: Mar 2, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Area of Science:

  • Geriatric Pharmacology
  • Clinical Pharmacy
  • Public Health

Background:

  • Older adults with multiple comorbidities often face complex medication regimens, increasing the risk of inappropriate prescribing.
  • Drugs with anticholinergic properties pose significant health risks and can negatively impact cognition, yet are often unrecognized.
  • Medication Therapy Management (MTM) interventions show potential for improving medication use, but targeted approaches for anticholinergic medications in older populations require further evaluation.

Purpose of the Study:

  • To evaluate the effectiveness of a targeted, patient-centered pharmacist-physician team MTM intervention in reducing the use of inappropriate anticholinergic medications in older adults.
  • To assess changes in medication appropriateness using the Medication Appropriateness Index (MAI) and the Anticholinergic Drug Scale (ADS) score.

Main Methods:

  • An 8-week, parallel-arm, randomized trial was conducted with older patients from the University of Kentucky's Alzheimer's Disease Center.
  • Participants were enrolled in a longitudinal cohort and randomized to either a targeted MTM intervention group or a control group.
  • Outcomes measured included changes in MAI and ADS scores from baseline to the end of the study, with adjustments for Clinical Dementia Rating (CDR).

Main Results:

  • The study enrolled 50 participants (70% women, 90% white, mean age 77.7 years), with 66% being cognitively intact at baseline.
  • The targeted MTM intervention group showed statistically significant improvements in both MAI (p=0.04) and ADS scores (p=0.03) compared to the control group.
  • Adjustments for CDR revealed significant CDR-adjusted differences, indicating the intervention's positive impact on medication appropriateness.

Conclusions:

  • The targeted MTM intervention effectively improved the appropriateness of anticholinergic medication use in older patients.
  • This approach successfully reduced the utilization of inappropriate anticholinergic medications, mitigating associated health risks.
  • The findings highlight the promise of multidisciplinary MTM interventions for optimizing medication outcomes in older adults.